These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38570342)
1. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study. Braud A; Auloge P; Meyer N; Bouvrais C; Gharbi M; Lang H; Gangi A; Lipsker D Cardiovasc Intervent Radiol; 2024 May; 47(5):567-572. PubMed ID: 38570342 [TBL] [Abstract][Full Text] [Related]
2. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Schermers B; Franke V; Rozeman EA; van de Wiel BA; Bruining A; Wouters MW; van Houdt WJ; Ten Haken B; Muller SH; Bierman C; Ruers TJM; Blank CU; van Akkooi ACJ Br J Surg; 2019 Apr; 106(5):519-522. PubMed ID: 30882901 [TBL] [Abstract][Full Text] [Related]
3. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251 [TBL] [Abstract][Full Text] [Related]
4. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. Reijers ILM; Rawson RV; Colebatch AJ; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Wouters MW; Saw RPM; van Houdt WJ; Zuur CL; Nieweg OE; Ch'ng S; Klop WMC; Spillane AJ; Long GV; Scolyer RA; van de Wiel BA; Blank CU JAMA Surg; 2022 Apr; 157(4):335-342. PubMed ID: 35138335 [TBL] [Abstract][Full Text] [Related]
5. The impact of the immunotherapy revolution on lymph nodal surgery. Eggermont AMM Bull Cancer; 2020 Jun; 107(6):640-641. PubMed ID: 31610910 [No Abstract] [Full Text] [Related]
6. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Eggermont AM Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171 [TBL] [Abstract][Full Text] [Related]
8. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Reijers ILM; Menzies AM; van Akkooi ACJ; Versluis JM; van den Heuvel NMJ; Saw RPM; Pennington TE; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Rozeman EA; Klop WMC; van Houdt WJ; Sikorska K; van der Hage JA; Grünhagen DJ; Wouters MW; Witkamp AJ; Zuur CL; Lijnsvelt JM; Torres Acosta A; Grijpink-Ongering LG; Gonzalez M; Jóźwiak K; Bierman C; Shannon KF; Ch'ng S; Colebatch AJ; Spillane AJ; Haanen JBAG; Rawson RV; van de Wiel BA; van de Poll-Franse LV; Scolyer RA; Boekhout AH; Long GV; Blank CU Nat Med; 2022 Jun; 28(6):1178-1188. PubMed ID: 35661157 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809 [TBL] [Abstract][Full Text] [Related]
10. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Shen L; Qi H; Chen S; Cao F; Xie L; Wu Y; Ma W; Song Z; Yuan H; Zhang T; Li D; Wen X; Chen Q; Li W; Zhang X; Fan W Cancer Immunol Immunother; 2020 Sep; 69(9):1713-1724. PubMed ID: 32333081 [TBL] [Abstract][Full Text] [Related]
15. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. Bhave P; Haydon A Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192 [TBL] [Abstract][Full Text] [Related]
16. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934 [TBL] [Abstract][Full Text] [Related]
17. Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma. Domingo-Musibay E; Heun JM; Nevala WK; Callstrom M; Atwell T; Galanis E; Erickson LA; Markovic SN Oncologist; 2017 Sep; 22(9):1026-e93. PubMed ID: 28679643 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052 [TBL] [Abstract][Full Text] [Related]
19. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Kounalakis N; Gao D; Gonzalez R; Becker M; Lewis K; Poust J; Pearlman N; Robinson W; McCarter M Immunotherapy; 2012 Jul; 4(7):679-86. PubMed ID: 22853754 [TBL] [Abstract][Full Text] [Related]
20. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy. Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Hashimoto A; Aiba S J Dermatol; 2019 May; 46(5):449-452. PubMed ID: 30908705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]